Compare Nuwellis Inc (NUWE) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Okta, Inc. — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Okta, Inc. trades at $231.41 (market cap $38.50B). The key difference: Okta, Inc. is far larger — about 17500× Nuwellis Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Okta, Inc. for 44 Days on average.
| NUWE | OKTA | |
|---|---|---|
Market Cap | $2.20M | $38.50B |
Volume | 121,544 | 2,479,621 |
Sector | Health | Technology |
52-Week High | $146.65 | $220.21 |
52-Week Low | $0.68 | $62.93 |
Typical Hold Time | 26 Days | 44 Days |
Enterprise Value | -$1.52M | $36.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Okta's stock trades at $228.38, up 4.76% in the last 24 hours, reflecting strong momentum. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth is robust, rising from $1.3B in 2022 to $2.6B in 2025, and profitability has improved significantly, turning a net loss into a $28M profit. Technical indicators show a bullish trend, with the current price near resistance at $228. Recent news highlights Okta's strategic focus on AI agent security, positioning it for future growth in the cybersecurity sector.
The outlook for Okta is positive, driven by strong earnings performance, revenue expansion, and strategic initiatives in AI. However, risks include high valuation multiples, such as a P/E of 132.66, and competitive pressures in the cybersecurity space. Analyst consensus is overwhelmingly bullish, with 73.58% recommending Buy, but investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
